Leucid Bio, a spin out company from King’s College London is focused on the development of new treatments for cancer. The company is developing a pioneering technology utilising engineered T cells.
VIEW WEBSITE >>
VIEW WEBSITE >>
Location: United Kingdom, England, London
Total raised: $15.87M
Investors 1
| Date | Name | Website |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.10.2021 | Series A | $15.87M | - |
Mentions in press and media 5
| Date | Title | Description |
| 20.10.2025 | Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London | PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future o... |
| 27.10.2021 | London-based biotech Leucid Bio raises £11.5M funding for hard-to-treat cancers | London-based biotech Leucid Bio raises £11.5M funding for hard-to-treat |
| 22.10.2021 | Leucid Bio Raises £11.5M in Series A Funding | Leucid Bio, a London UK-based biotech company, raised £11.5M in series A funding. The round was led by Epidarex and new investor Vulpes Investment Management with participation from new investors 2Invest and Future Fund of the British Busin... |
| 22.10.2021 | Is former WeWork CEO Adam Neumann preparing his second act? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Some two years ago, office-sharing company WeWork withdrew its IPO plans after struggling to find... |
| 21.10.2021 | Leucid Bio Raises £11.5Million In Series A Financing To Develop Next Generation Of Innovative Chimeric Antigen Receptor T Cell (CAR-T) Therapies | Leucid Bio a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces that it has successfully raised £11.5 million in a Series A financing round. The investment was led by Epidarex and new invest... |